Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 6/20 | 0.68 |
| ▸ | NT5E | P21589 | 1/20 | 0.68 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.63 |
| ▸ | KRAS | P01116 | 5/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.58 |
| ▸ | TYMP | P19971 | 1/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17440173 | 1.00 | HINT1 (0.68) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL10904155 | 0.88 | TYMP (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL1904550 | 0.88 | TYMP (0.76) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3514472 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL3970953 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL17355882 | 0.88 | HINT1 (0.73) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2335177 | 0.87 | HINT1 (0.69) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL7111080 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| SCHEMBL2014087 | 0.87 | HINT1 (0.72) | HINT1NT5EGSK3ARPS6KA3MAPK14 | |
| 2'-Beta-Methyl-Guanosine SCHEMBL11965261 | 0.87 | HINT1 (0.75) | HINT1NT5EGSK3ARPS6KA3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| US-20240174732-A1 | NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONAL POLYPEPTIDES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240173400-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-2931319-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | Moderna Therapeutics, Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2918275-A1 | Alternative nucleic acid molecules and uses thereof | Roy, Atanu (US) | 2015-09-16 | — | — | EP | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015058069-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015051214-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015048744-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | HINT1 4825/4885NT5E 4362/4885GSK3A 4713/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | HINT1 389/4885NT5E 434/4885GSK3A 3949/4885 |
| US-20240174732-A1 | NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONAL POLYPEPTIDES AND THEIR USE IN TREATING CANCER | STING1, TRDMT1, TLR3 | HINT1 1925/4885NT5E 204/4885GSK3A 3677/4885 |
| US-20240173400-A1 | HERPES SIMPLEX VIRUS VACCINE | STING1, RPL23, RPL17 | HINT1 1382/4885NT5E 2951/4885GSK3A 2540/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | HINT1 4080/4885NT5E 213/4885GSK3A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.